Deals of the day-Mergers and acquisitions

Johnson & Johnson

Today 21:06

Adds: Financial Leasing, Goldman Sachs and CVC  Updates: BASF
Oct 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2020 GMT on Friday:

**  CVC CVC.AS  and Belgian investment firm GBL GBLB.BR which this month raised their bid for Italian pharmaceutical group Recordati RECI.MI  to €53 a share, had secured a 74.3% stake in the firm by the end of the offer period, a regulatory filing showed. nL6N467135
 
** Private equity firm Inflexion said on Friday it would sell a majority stake in British testing and safety compliance company Celnor Group to Goldman Sachs GS.N Alternatives. nL6N4690TC
 
** Chinese state-owned investment group Shanghai International offered to buy a 51% stake in Haitong Unitrust International Financial Leasing 1905.HK for about $1.16 billion, according to a joint statement. nL4N46918E
  
** Spanish soccer club Valencia CF said an investment group backed by KKR co-founders George Roberts and Henry Kravis would buy a 42% stake in the club in a deal valuing it at €1.25 billion ($1.4 billion) including debt. nL1N4690JL
     
** BASF BASFn.DE has increased its takeover offer for German chemicals manufacturer Evonik Industries EVKn.DE to €24 per share, two people close to the deal told Reuters. nL4N469106 
     
 ** Hong Kong-listed mining and metals company MMG 1208.HK offered on Friday to guarantee the supply of ferronickel to European stainless steel producers, in an effort to address EU antitrust concerns over its $500 million bid for Anglo American's AAL.L Brazilian nickel business. nL6N4690U4
     
** Malteurop, one of the world's largest producers of beer ingredient malt, has acquired Chunlei Malting Co to expand its capacity in China, the French company said. nL8N4690TG
     
** Smith & Nephew's SN.L talks with Johnson & Johnson JNJ.N to combine with the US group's orthopaedics division fell apart after the London-listed group refused to agree to its former CEO leading the merged business, the Financial Times reported , citing people familiar with the matter. nL6N4690EV
     
** Gilead Sciences GILD.O said on Thursday it will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental bowel disease treatment, for $1.275 billion in cash upfront. nL4N46825Z

 (Compiled by Rajarshi Roy, Miraanta Lowrance and Varun Sahay in Bengaluru)
 ((Varun.sahay@thomsonreuters.com))